{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:38:52Z","timestamp":1792543132539,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johnson & Johnson"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This retrospective study involving 225 centers assessed\n                    <jats:italic>TP53<\/jats:italic>\n                    and IGHV molecular status and stereotyped BcR IG subsets in a large cohort of patients with CLL in Spain using data from the RED53 project. Three analytical reference centers determined the mutational status of treatment-na\u00efve CLL patients requiring treatment following the ERIC guidelines between May 2016 and March 2021. Of 1097 patients included (58.4% men), 90.8% had unmutated\n                    <jats:italic>TP53<\/jats:italic>\n                    . Of the 100 patients (9.2%) with mutated\n                    <jats:italic>TP53<\/jats:italic>\n                    , most (97.0%) had single-hit\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations, of which 88.3% were pathogenic. IGHV-UM mutational status (57.8%) was slightly more common than IGHV-M (33.2%). Of patients with mutated\n                    <jats:italic>TP53<\/jats:italic>\n                    , 66.7% had IGHV-UM and 30.0% IGHV-M. Stereotyped Ig BCR subsets were identified in 9.2% of patients, with the most frequent being CLL#1 (23.2%), CLL#2 (24.0%), and CLL#6 (10.7%). The frequencies of\n                    <jats:italic>TP53<\/jats:italic>\n                    and IGHV mutations were similar to those reported in other international series. The RED53 project enabled molecular testing to be incorporated into routine practice to guide treatment decisions.\n                  <\/jats:p>","DOI":"10.1007\/s12185-026-04285-0","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:40:10Z","timestamp":1792496410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TP53 mutations and IGHV in na\u00efve chronic lymphocytic leukemia: retrospective analysis of data from a Spanish collaborative network"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9467-932X","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Terol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Ferrer-Lores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Alcoceba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azahara","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Javier","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"4285_CR1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. IwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood"},{"key":"4285_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.8","author":"G Fabbri","year":"2016","unstructured":"Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016. https:\/\/doi.org\/10.1038\/nrc.2016.8.","journal-title":"Nat Rev Cancer"},{"key":"4285_CR3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.231027","author":"S Jaramillo","year":"2020","unstructured":"Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL study group. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2019.231027.","journal-title":"Haematologica"},{"key":"4285_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/joim.12455","volume":"279","author":"P Baliakas","year":"2016","unstructured":"Baliakas P, Mattsson M, Stamatopoulos K, Rosenquist R. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? J Intern Med. 2016;279:347\u201357. https:\/\/doi.org\/10.1111\/joim.12455.","journal-title":"J Intern Med"},{"key":"4285_CR5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v46.2.219.bloodjournal462219","author":"KR Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975. https:\/\/doi.org\/10.1182\/blood.v46.2.219.bloodjournal462219.","journal-title":"Blood"},{"key":"4285_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","author":"JL Binet","year":"1981","unstructured":"Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981. https:\/\/doi.org\/10.1002\/1097-0142(19810701)48:1%3c198::AID-CNCR2820480131%3e3.0.CO;2-V.","journal-title":"Cancer"},{"key":"4285_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics11050853","volume":"11","author":"C P\u00e9rez-Carretero","year":"2021","unstructured":"P\u00e9rez-Carretero C, Gonz\u00e1lez-Gasc\u00f3n-y-mar\u00edn I, Rodr\u00edguez-Vicente AE, Quijada-\u00e1lamo M, Hern\u00e1ndez-Rivas J\u00c1, Hern\u00e1ndez-S\u00e1nchez M, et al. The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment. Diagnostics. 2021;11:1\u201330. https:\/\/doi.org\/10.3390\/diagnostics11050853.","journal-title":"Diagnostics"},{"key":"4285_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.08.005","author":"CI Amaya-Chanaga","year":"2016","unstructured":"Amaya-Chanaga CI, Rassenti LZ. Biomarkers in chronic lymphocytic leukemia: clinical applications and prognostic markers. Best Pract Res Clin Haematol. 2016. https:\/\/doi.org\/10.1016\/j.beha.2016.08.005.","journal-title":"Best Pract Res Clin Haematol"},{"key":"4285_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.6.1848","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999. https:\/\/doi.org\/10.1182\/blood.v94.6.1848.","journal-title":"Blood"},{"key":"4285_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200012283432602","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Leupolt E, Kr\u00f6ber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000. https:\/\/doi.org\/10.1056\/nejm200012283432602.","journal-title":"N Engl J Med"},{"key":"4285_CR11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v84.9.3148.bloodjournal8493148","author":"E Wattel","year":"1994","unstructured":"Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994. https:\/\/doi.org\/10.1182\/blood.v84.9.3148.bloodjournal8493148.","journal-title":"Blood"},{"key":"4285_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMOA2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739\u201354. https:\/\/doi.org\/10.1056\/NEJMOA2213093.","journal-title":"N Engl J Med"},{"key":"4285_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS16071290","volume":"16","author":"A Visentin","year":"2024","unstructured":"Visentin A, Frazzetto S, Trentin L, Chiarenza A. Innovative combinations, cellular therapies and bispecific antibodies for chronic lymphocytic leukemia: a narrative review. Cancers (Basel). 2024;16:1290. https:\/\/doi.org\/10.3390\/CANCERS16071290.","journal-title":"Cancers (Basel)"},{"key":"4285_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000533704","volume":"147","author":"S Kang","year":"2024","unstructured":"Kang S, Ahn IE. Prognostic markers in the era of targeted therapies. Acta Haematol. 2024;147:35\u201348. https:\/\/doi.org\/10.1159\/000533704.","journal-title":"Acta Haematol"},{"key":"4285_CR15","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762\/SUPPL_FILE\/SUPPLEMENTAL_TABLE.XLS","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, Denzel T, H\u00e4be S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clinl Oncol. 2010;28:4473\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.27.8762\/SUPPL_FILE\/SUPPLEMENTAL_TABLE.XLS. ([Internet]).","journal-title":"J Clinl Oncol"},{"issue":"7","key":"4285_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","volume":"38","author":"J Malcikova","year":"2024","unstructured":"Malcikova J, Pavlova S, Baliakas P, Chatzikonstantinou T, Tausch E, Catherwood M, et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia\u20142024 update. Leukemia. 2024;38(7):1455\u201368. https:\/\/doi.org\/10.1038\/s41375-024-02267-x.","journal-title":"Leukemia"},{"key":"4285_CR17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.6.1840.418k06_1840_1847","author":"RN Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999. https:\/\/doi.org\/10.1182\/blood.v94.6.1840.418k06_1840_1847.","journal-title":"Blood"},{"key":"4285_CR18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393694","author":"A Agathangelidis","year":"2012","unstructured":"Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012. https:\/\/doi.org\/10.1182\/blood-2011-11-393694.","journal-title":"Blood"},{"key":"4285_CR19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600874","author":"P Baliakas","year":"2015","unstructured":"Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015. https:\/\/doi.org\/10.1182\/blood-2014-09-600874.","journal-title":"Blood"},{"key":"4285_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04331-9","author":"F Bosch","year":"2021","unstructured":"Bosch F, Navarro B, Crespo M, Alcoceba M, S\u00e1nchez JB, Taz\u00f3n B, et al. Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. Ann Hematol. 2021. https:\/\/doi.org\/10.1007\/s00277-020-04331-9.","journal-title":"Ann Hematol"},{"key":"4285_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.125","author":"R Rosenquist","year":"2017","unstructured":"Rosenquist R, Ghia P, Hadzidimitriou A, Sutton LA, Agathangelidis A, Baliakas P, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017. https:\/\/doi.org\/10.1038\/leu.2017.125.","journal-title":"Leukemia"},{"key":"4285_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","volume":"32","author":"J Malcikova","year":"2018","unstructured":"Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia\u2014update on methodological approaches and results interpretation. Leukemia. 2018;32:1070\u201380. https:\/\/doi.org\/10.1038\/s41375-017-0007-7.","journal-title":"Leukemia"},{"key":"4285_CR23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016. https:\/\/doi.org\/10.1182\/blood-2015-06-651125.","journal-title":"Blood"},{"key":"4285_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.263","author":"A Stengel","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017. https:\/\/doi.org\/10.1038\/leu.2016.263.","journal-title":"Leukemia"},{"key":"4285_CR25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1815281","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/nejmoa1815281.","journal-title":"N Engl J Med"},{"key":"4285_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/S41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16:684\u2013701. https:\/\/doi.org\/10.1038\/S41571-019-0239-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"4285_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000412","author":"JA Burger","year":"2019","unstructured":"Burger JA. Bruton tyrosine kinase inhibitors: present and future. Cancer J. 2019. https:\/\/doi.org\/10.1097\/PPO.0000000000000412.","journal-title":"Cancer J"},{"key":"4285_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.10.012","author":"S Molica","year":"2021","unstructured":"Molica S, Giannarelli D, Montserrat E. Comparison between venetoclax-based and Bruton tyrosine kinase inhibitor-based therapy as upfront treatment of chronic lymphocytic leukemia (CLL): a systematic review and network meta-analysis. Clin Lymphoma Myeloma Leuk. 2021. https:\/\/doi.org\/10.1016\/j.clml.2020.10.012.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4285_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00512-0","author":"DA Bond","year":"2019","unstructured":"Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib. Curr Hematol Malig Rep. 2019. https:\/\/doi.org\/10.1007\/s11899-019-00512-0.","journal-title":"Curr Hematol Malig Rep"},{"key":"4285_CR30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4890","author":"C Brieghel","year":"2021","unstructured":"Brieghel C, Aarup K, Torp MH, Andersen MA, Yde CW, Tian X, et al. Clinical outcomes in patients with multi-hit TP53 chronic lymphocytic leukemia treated with ibrutinib. Clin Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4890.","journal-title":"Clin Cancer Res"},{"key":"4285_CR31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1313984","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014. https:\/\/doi.org\/10.1056\/nejmoa1313984.","journal-title":"N Engl J Med"},{"key":"4285_CR32","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208\u201315. https:\/\/doi.org\/10.1182\/blood-2015-06-651125.","journal-title":"Blood"},{"key":"4285_CR33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3324\/HAEMATOL.2017.165605","volume":"102","author":"LA Sutton","year":"2017","unstructured":"Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, et al. Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. Haematologica. 2017;102:968\u201371. https:\/\/doi.org\/10.3324\/HAEMATOL.2017.165605.","journal-title":"Haematologica"},{"key":"4285_CR34","doi-asserted-by":"publisher","first-page":"059","DOI":"10.1055\/S-0044-1779668","volume":"11","author":"C Mu\u00f1oz-Novas","year":"2024","unstructured":"Mu\u00f1oz-Novas C, Gonz\u00e1lez-Gasc\u00f3n-y-Mar\u00edn I, Figueroa I, S\u00e1nchez-Paz L, P\u00e9rez-Carretero C, Quijada-\u00c1lamo M, et al. Association of cytogenetics aberrations and ighv mutations with outcome in chronic lymphocytic leukemia patients in a real-world clinical setting. Glob Med Genet. 2024;11:059\u201368. https:\/\/doi.org\/10.1055\/S-0044-1779668. ([Internet]).","journal-title":"Glob Med Genet"},{"key":"4285_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/BLOOD-2006-03-012948","volume":"109","author":"K Stamatopoulos","year":"2007","unstructured":"Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109:259\u201370. https:\/\/doi.org\/10.1182\/BLOOD-2006-03-012948.","journal-title":"Blood"},{"key":"4285_CR36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clml.2012.03.005","volume":"12","author":"T Karan-Djurasevic","year":"2012","unstructured":"Karan-Djurasevic T, Palibrk V, Kostic T, Spasovski V, Nikcevic G, Srzentic S, et al. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012;12:252\u201360. https:\/\/doi.org\/10.1016\/j.clml.2012.03.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4285_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/14719037.2013.792380","author":"M Torchia","year":"2015","unstructured":"Torchia M, Calabr\u00f2 A, Morner M. Public\u2013private partnerships in the health care sector: a systematic review of the literature. Public Manag Rev. 2015. https:\/\/doi.org\/10.1080\/14719037.2013.792380.","journal-title":"Public Manag Rev"},{"key":"4285_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/1087724X16657830","author":"GA Hodge","year":"2017","unstructured":"Hodge GA, Greve C. On public\u2013private partnership performance: a contemporary review. Public Works Manag Policy. 2017. https:\/\/doi.org\/10.1177\/1087724X16657830.","journal-title":"Public Works Manag Policy"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04285-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:05:17Z","timestamp":1792541117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04285-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":38,"alternative-id":["4285"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04285-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.T. reports a consultant or advisory board role for Johnson and Johnson, AbbVie, Gilead, BMS, Roche, and Takeda, received research funding from Johnson and Johnson and Gilead, and received funding for travel and accommodation expenses from Johnson and Johnson, AbbVie, Gilead, Roche, and Takeda. B.F. reports a consultant or advisory board role for Johnson and Johnson. F.B. reports a consultant role for Novartis, AbbVie, Johnson and Johnson, Gilead, Mundipharma, Lilly, BeiGene, and AstraZeneca, and received honoraria from Novartis, AbbVie, Johnson and Johnson, Gilead, Mundipharma, Roche, AstraZeneca, Takeda, and Celgene. M.G. reports a role on Board of Directors or advisory committees for AstraZeneca, Gilead, Roche, Johnson and Johnson, and AbbVie and a role as a lecturer for AstraZeneca, Gilead, Roche, Johnson and Johnson, and AbbVie. M.C. reports a role as a consultant for Johnson and Johnson and received research funding from AstraZeneca and Roche\/Genentech. M.A. has received honoraria from Johnson and Johnson and AstraZeneca and honoraria for travel expenses from Johnson and Johnson and AstraZeneca. M.V. is a Johnson and Johnson employee. A.S., A.F., and J.F.C. report no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}